Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Mirati Therapeutics (MRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,261,776
  • Shares Outstanding, K 32,520
  • Annual Sales, $ 0 K
  • Annual Income, $ -70,430 K
  • 36-Month Beta 1.83
  • Price/Sales 133.24
  • Price/Cash Flow N/A
  • Price/Book 5.38

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.80
  • Number of Estimates 5
  • High Estimate -0.62
  • Low Estimate -0.90
  • Prior Year -0.67
  • Growth Rate Est. (year over year) -19.40%

Price Performance

See More
Period Period Low Period High Performance
1-Month
28.50 +38.77%
on 10/22/18
44.99 -12.09%
on 10/17/18
-4.43 (-10.07%)
since 10/16/18
3-Month
28.50 +38.77%
on 10/22/18
61.70 -35.90%
on 09/21/18
-19.30 (-32.80%)
since 08/16/18
52-Week
15.35 +157.65%
on 12/12/17
65.35 -39.48%
on 07/31/18
+20.55 (+108.16%)
since 11/16/17

Most Recent Stories

More News
Mirati Presents Preliminary Biomarker Data From Ongoing Phase 2 Clinical Trial Of Sitravatinib In Combination With Nivolumab At The SITC 33rd Annual Meeting

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, announced preliminary biomarker data from the ongoing Phase 2 clinical trial of sitravatinib in combination with nivolumab...

MRTX : 39.62 (+2.11%)
Mirati Presents Data From Ongoing Phase 2 Clinical Trial Of Mocetinostat In Combination With Durvalumab At The SITC 33rd Annual Meeting

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, announced data from the ongoing Phase 2 clinical trial of mocetinostat in combination with durvalumab (IMFINZI®) in...

MRTX : 39.62 (+2.11%)
Mirati Therapeutics Announces First Patient Dosed In Phase 1b Clinical Trial Of Sitravatinib In Combination With Anti-PD1 Antibody Tislelizumab In Patients With Advanced Solid Tumors

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced dosing of the first patient under its collaboration agreement with BeiGene, Ltd. (NASDAQ: BGNE; HKEX:...

BGNE : 127.06 (+0.05%)
MRTX : 39.62 (+2.11%)
Mirati: 3Q Earnings Snapshot

SAN DIEGO (AP) _ Mirati Therapeutics Inc. (MRTX) on Tuesday reported a loss of $27.6 million in its third quarter.

MRTX : 39.62 (+2.11%)
Mirati Therapeutics Reports Third Quarter Financial Results

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter ended September 30, 2018.

MRTX : 39.62 (+2.11%)
Mirati Therapeutics Announces Submission of IND Application for MRTX849, a KRAS G12C Inhibitor, to Treat Non-Small Cell Lung Cancer and Colorectal Cancer

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, announced today that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration...

MRTX : 39.62 (+2.11%)
Gilead Sciences is Among the Companies in the Biotechnology Industry with the Best Relative Performance (GILD , AMGN , MDXG , MRTX, VRTX )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

MDXG : 2.6400 (+9.54%)
GILD : 69.44 (-0.49%)
AMGN : 195.00 (+1.33%)
MRTX : 39.62 (+2.11%)
Research Report Identifies CSG Systems International, Zumiez, Urban Outfitters, Mirati Therapeutics, Applied Materials, and Xencor with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of CSG Systems International,...

AMAT : 35.37 (+1.00%)
ZUMZ : 20.76 (-0.76%)
CSGS : 36.74 (+0.11%)
XNCR : 39.36 (+1.03%)
MRTX : 39.62 (+2.11%)
URBN : 36.93 (-2.76%)
Mirati Therapeut is Among the Companies in the Biotechnology Industry with the Best Relative Performance (MRTX, DVAX , SPPI , ACOR , IONS )

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

SPPI : 13.24 (+3.12%)
DVAX : 12.21 (+1.50%)
MRTX : 39.62 (+2.11%)
Downtrend Call Working As Mirati Therapeut Stock Falls 25.0% (MRTX)

SmarTrend identified a Downtrend for Mirati Therapeut (NASDAQ:MRTX) on October 2nd, 2018 at $47.07. In approximately 3 weeks, Mirati Therapeut has returned 25.04% as of today's recent price of $35.28....

MRTX : 39.62 (+2.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade MRTX with:

Business Summary

Mirati Therapeutics, Inc. is a biopharmaceutical company. It engaged in the development of novel therapeutics for the treatment of cancer. Mirati Therapeutics, Inc., formerly known as MethylGene Inc., is based in Montreal, Canada.

See More

Key Turning Points

2nd Resistance Point 40.04
1st Resistance Point 39.42
Last Price 39.62
1st Support Level 37.66
2nd Support Level 36.52

See More

52-Week High 65.35
Fibonacci 61.8% 46.25
Fibonacci 50% 40.35
Last Price 39.62
Fibonacci 38.2% 34.45
52-Week Low 15.35

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar